HORSHAM, Pa.--(BUSINESS WIRE)--Reliefband Technologies, LLC, an innovator in wearable technology that treats motion sickness, is debuting its advanced 2.0 technology at CES in 2018. Reliefband® technology provides an effective and drug-free solution for controlling nausea, retching and vomiting associated with motion sickness, morning sickness, virtual reality gaming, postoperative care* and chemotherapy induced nausea and vomiting (CINV).
According to Forbes, the global wearable technology market is estimated to reach revenue of $34 billion by 2020 and further doubling by 2023. The Wearable Technology Market is saturated with fitness trackers, health monitors and smart watches. Reliefband is a trailblazer in the “wearable treatable” category with FDA-cleared, clinically–proven, neuro-stimulation for the drug-free treatment of nausea.
Led by a Board of Directors of seasoned consumer and healthcare executives, “Reliefband Technologies is a great growth investment and one that I’m excited to see open up a new field in the wearable tech market,” according to Bill Gantz, President of PathoCapital LLC, a private investment firm and Board Chairman of Reliefband Technologies.
With enhanced aesthetics, intuitive controls and a more consumer friendly design, the Reliefband 2.0 is ideal for both occasional and all day use. Unlike other key players in the global wearable technology market - like Apple, Fitbit and Jawbone - Reliefband’s technology actually treats people instead of just tracking their activity.
“Uniquely designed for optimal usability, Reliefband devices accommodate the uniqueness of each person’s individual physiology and sensitivity,” indicates Nick Spring, the company’s President and CEO. “The Neurowave Pulse Generator, a patented technology at the heart of the devices, holds proprietary electronic components and software that control, develop and deliver unique pulses, with highly specific characteristics. It is this very precise technology that will quickly control nausea from motion sickness and other significant indications. Endorsed by healthcare professionals, this easy-to-use, comfortable and adjustable wearable helps put people back in control, so they can live their lives in full motion.
The Company has raised substantial funding to develop the next generation of Reliefband technology to enhance product comfort, usability and design. They have also tested the commercial viability of the technology for broad consumer acceptance.
Since 2014, the Company has demonstrated their technology in the Over-The-Counter healthcare market by significantly growing unit and dollar sales.
For more information please visit http://www.reliefband.com.
EDITOR'S NOTE: For more information about Reliefband® and
to arrange to speak with a company spokesperson, please contact Nancy
Trent or Pamela Wadler at 212-966-0024 or pam@trentandcompany.com.
*- effective as an adjunct to antiemetic therapy in reducing postoperative nausea.
